1B1 Stock Overview
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Molecure S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł3.28 |
| 52 Week High | zł5.35 |
| 52 Week Low | zł3.28 |
| Beta | 2.2 |
| 1 Month Change | -14.71% |
| 3 Month Change | -27.94% |
| 1 Year Change | -31.41% |
| 3 Year Change | -69.34% |
| 5 Year Change | n/a |
| Change since IPO | -69.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1B1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.5% | 1.6% | -0.3% |
| 1Y | -31.4% | -26.4% | 2.8% |
Return vs Industry: 1B1 underperformed the German Pharmaceuticals industry which returned -26.4% over the past year.
Return vs Market: 1B1 underperformed the German Market which returned 2.8% over the past year.
Price Volatility
| 1B1 volatility | |
|---|---|
| 1B1 Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1B1's share price has been volatile over the past 3 months.
Volatility Over Time: 1B1's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 109 | Marcin Szumowski | molecure.com |
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program.
Molecure S.A. Fundamentals Summary
| 1B1 fundamental statistics | |
|---|---|
| Market cap | €55.73m |
| Earnings (TTM) | -€4.04m |
| Revenue (TTM) | €318.93k |
174.7x
P/S Ratio-13.8x
P/E RatioIs 1B1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1B1 income statement (TTM) | |
|---|---|
| Revenue | zł1.38m |
| Cost of Revenue | zł1.80m |
| Gross Profit | -zł424.51k |
| Other Expenses | zł16.99m |
| Earnings | -zł17.41m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 29, 2024
| Earnings per share (EPS) | -1.03 |
| Gross Margin | -30.86% |
| Net Profit Margin | -1,265.69% |
| Debt/Equity Ratio | 0% |
How did 1B1 perform over the long term?
See historical performance and comparison